Friday-Saturday, May 13-14, 2016

Memorial Sloan Kettering Symposium on Lymphoma

State of the art in biology, therapy, and patient care

CONFERENCE LOCATION
MEMORIAL SLOAN KETTERING CANCER CENTER
ZUCKERMAN RESEARCH CENTER
NEW YORK

To register or for more information, please go to:
www.mskcc.org/lymphoma2016
You won’t want to miss this unprecedented symposium focused on the future of Lymphoma with many of the world’s leading experts.

TARGET AUDIENCE
Medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of lymphoma.

COURSE OVERVIEW
This symposium will feature updated information on lymphoma biology, diagnosis, immunology, and genetics, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphomas. Faculty will review the current standard of care and present their own perspectives on how they treat various types of lymphomas. Participants will have the opportunity to discuss diagnostic and management cases, and how to incorporate biologic and genetic biomarkers into clinical practice and clinical trials.
SYMPOSIUM CHAIR

Anas Younes MD
Chief, Lymphoma Service

ORGANIZING COMMITTEE

Ahmet Dogan MD PhD

Craig Moskowitz MD

Hans Guido Wendel MD

Joachim Yahalom MD FACR

Andrew Zelenetz MD PhD

www.mskcc.org/lymphoma2016
Memorial Sloan Kettering Symposium on Lymphoma

State of the art in biology, therapy, and patient care

Friday-Saturday, May 13-14, 2016

www.mskcc.org/lymphoma2016

MSK FACULTY

Maria Arcila MD
Connie Batlevi MD PhD
John F. Gerecitano MD PhD
Paul Hamlin MD
Steven Horwitz MD
Andrew M. Intlekofer MD PhD
Anita Kumar MD
Matthew Matasar MD
Alison Moskowitz MD
Ariela Noy MD
M. Lia Palomba MD
Carol Portlock MD
Mikhail Roshal MD
Michel Sadelain MD PhD
David Straus MD
Jedd D. Wolchok MD PhD

GUEST FACULTY

Ranjana Advani MD
Stanford University
Steve Ansell MD PhD
Mayo Clinic
Francesco D’Amore MD
Aarhus University
Riccardo Dalla-Favera MD
Columbia University
Martin Dreyling MD
Ludwig Maximilian University
Randy Gascoyne MD
BC Cancer Agency
Elaine Jaffe MD
National Cancer Institute
Ronald Levy MD
Stanford University
Barbara Pro MD
Northwestern University
John Radford MD
University of Manchester
Louis Staudt MD PhD
National Cancer Institute
Gilles Salles MD PhD
Hospices Civils de Lyon
Wyndham Wilson MD PhD
National Cancer Institute
Thomas Witzig MD
Mayo Clinic

MSK conducts one of the largest clinical research programs in the world, aimed at improving the prevention, diagnosis, and treatment of cancer. In December 2013, our physicians were leading 1,259 clinical research studies for pediatric and adult cancers.
Friday, May 13

7:00-8:00am  BREAKFAST & REGISTRATION
8:00-8:05am  Welcoming Remarks and Introduction to the MSK Lymphoma Symposium and Grand Rounds Lecture  
Anas Younes MD
8:05-8:50am  DEPARTMENT OF MEDICINE GRAND ROUNDS  
Advances in Immunotherapy of Lymphoma  
Ronald Levy MD

INTRODUCTION  
CHAIRS Anas Younes MD and Elaine Jaffe MD

9:15-9:45am  Lymphoma Classification  
Elaine Jaffe MD
9:45-10:15am  Advances in Molecular Diagnostics  
Maria Arcila MD
10:15-10:35am  Advances in Radiation Oncology  
Joachim Yahalom MD FACR
10:35-10:50am  Survivorship Program for Patients with Lymphoma  
Matthew Matasar MD
10:50-11:30am  State of The Lymphoma at MSK  
Anas Younes MD
11:30am-12:30pm  LUNCH

DIFFUSE LARGE B CELL LYMPHOMA-I  
CHAIRS Louis Staudt MD PhD and Thomas Witzig MD

12:30-12:45pm  DLBCL Overview  
Thomas Witzig MD
12:45-1:15pm  Advances in DLBCL Biology  
Riccardo Dalla-Favera MD
1:15-1:45pm  Mechanism-Based Therapy of Lymphoma  
Louis Staudt MD PhD
1:45-2:05pm  Application of Genome Sequencing in Hematopathology Practice  
Ahmet Dogan MD PhD
2:05-2:20pm  How I Treat DLBCL  
Andrew Zelenetz MD PhD
2:20-2:35pm  How I Treat Double Hit Lymphoma  
Wyndham Wilson MD PhD
2:35-2:50pm  How I Treat Burkitt Lymphoma  
Ariela Noy MD
2:50-3:15pm  CLINICAL CASES  
CHAIRS Witzig, Zelenetz, Wilson, Hamlin, Noy, Jaffe
3:15-3:30pm  BREAK
Friday, May 13

HODGKIN LYMPHOMA
CHAIRS John Radford MD and Craig Moskowitz MD

3:30-4:00pm
HL Overview
John Radford MD

4:00-4:30pm
Advances in HL Biology
Randy Gascoyne MD

4:30-4:45pm
HL Genetics
Mikhail Roshal MD

4:45-5:00pm
How I Treat Newly Diagnosed HL
David Straus MD

5:00-5:15pm
How I Treat Relapsed HL
Craig Moskowitz MD

5:15-5:30pm
Novel Therapy for Hodgkin Lymphoma
Alison Moskowitz MD

5:30-6:00pm
CLINICAL CASES
CHAIRS Radford, Moskowitz, Younes, Ansell, Straus, Yahalom, Gascoyne

6:00-7:00pm
COCKTAIL RECEPTION
Saturday, May 14

7:00-8:00am  BREAKFAST

**FOCUS ON IMMUNO ONCOLOGY**
**CHAIRS** Ronald Levy MD and Anas Younes MD

8:00-8:30am  Overview of Immune Checkpoint Inhibitors in Cancer
Jedd D. Wolchok MD PhD

8:30-9:00am  Novel Immune Therapy Strategies
Ronald Levy MD

9:00-9:30am  Advances in CAR T cell Therapy
Michel Sadelain

9:30-9:50am  Immune Checkpoint Inhibitors in Lymphoma
Steve Ansell MD PhD

9:50-10:10am  Novel Bispecific Antibodies and ADCs
Ranjana Advani MD

10:10-10:30am  Novel Immune Therapy Combinations
Anas Younes MD

**TRIALS IN PROGRESS**
**CHAIRS** Paul Hamlin MD and John Gerecitano MD PhD

10:30-10:40am  Trials in Progress with Immune Checkpoint Inhibitors
A. Moskowitz, Palomba

10:40-10:50am  Trials in Progress with ADC
Hamlin, Horwitz

10:50-11:00am  Trials in Progress with BCL2 Inhibitors
Zelenetz, Gerecitano

11:00-11:10am  Trials in Progress with PI3K Inhibitors
Horwitz, Gerecitano

11:10-11:20am  Trials with Biomarker Selection
(CREBBP IDH2, EZH2,MDM2)
Intlekofer, Batlevi

11:20-11:30am  Trials in Progress with BCR Signaling Inhibitors
Noy, Hamlin

11:30-11:45am  BREAK
Saturday, May 14

**T CELL LYMPHOMA**

**CHAIRS** F. D'Amore and S. Horwitz

11:45am-12:15pm  
**T Cell Lymphoma Overview**  
Francesco D'Amore MD

12:15-12:30pm  
**How I Treat Newly Diagnosed PTCL**  
Steven Horwitz MD

12:30-12:45pm  
**How I Treat Patients with Relapsed T Cell Lymphoma**  
Barbara Pro MD

12:45-1:00pm  
**CLINICAL CASES**

**CHAIRS** Horwitz, D'Amore, Pro, Advani, Yahalom, Jaffe, Dogan

1:00-2:00pm  
**LUNCH**

**MANTLE CELL AND FOLLICULAR LYMPHOMA**

**CHAIRS** Martin Dreyling MD and Gilles Salles MD PhD

2:00-2:30pm  
**MCL Overview**  
Martin Dreyling MD

2:30-3:00pm  
**How I Treat MCL**  
Paul Hamlin MD

3:00-3:30pm  
**Follicular Lymphoma Overview**  
Gilles Salles MD

3:30-4:00pm  
**Insights into Follicular Lymphoma Biology**  
Hans Guido Wendel MD

4:00-4:30pm  
**Epigenetic Modifiers in the Pathogenesis of Follicular Lymphoma**  
Laura Pasqualucci MD

4:30-5:00pm  
**How I Treat Newly Diagnosed Indolent Lymphoma**  
Carol Portlock MD

5:00-5:15pm  
**How I Treat Waldenstrom Macroglobulinemia**  
M. Lia Palomba MD

5:15-5:45pm  
**CLINICAL CASES**

**CHAIRS** Dreyling, Salles, Portlock, Gascoyne, Dogan

5:45pm  
**CLOSING REMARKS**

Anas Younes MD
Friday-Saturday, May 13-14, 2016
www.mskcc.org/lymphoma2016

Saturday, May 14
T CELL LYMPHOMA
CHAIRS F. D’Amore and S. Horwitz
11:45am-12:15pm
T Cell Lymphoma Overview
Francesco D’Amore MD

12:15-12:30pm
How I Treat Newly Diagnosed PTCL
Steven Horwitz MD

12:30-12:45pm
How I Treat Patients with Relapsed T Cell Lymphoma
Barbara Pro MD

12:45-1:00pm
CLINICAL CASES
CHAIRS Horwitz, D’Amore, Pro, Advani, Yahalom, Jaffe, Dogan

1:00-2:00pm
LUNCH

MANTLE CELL AND FOLLICULAR LYMPHOMA
CHAIRS Martin Dreyling MD and Gilles Salles MD PhD
2:00-2:30pm
MCL Overview
Martin Dreyling MD

2:30-3:00pm
How I Treat MCL
Paul Hamlin MD

3:00-3:30pm
Follicular Lymphoma Overview
Gilles Salles MD

3:30-4:00pm
Insights into Follicular Lymphoma Biology
Hans Guido Wendel MD

4:00-4:30pm
Epigenetic Modifiers in the Pathogenesis of Follicular Lymphoma
Laura Pasqualucci MD

4:30-5:00pm
How I Treat Newly Diagnosed Indolent Lymphoma
Carol Portlock MD

5:00-5:15pm
How I Treat Waldenstrom Macroglobulinemia
M. Lia Palomba MD

5:15-5:45pm
CLINICAL CASES
CHAIRS Dreyling, Salles, Portlock, Gascoyne, Dogan

5:45pm
CLOSING REMARKS
Anas Younes MD

REGISTRATION

$400  MDs, PhDs, DOs
$280  MSK Alliance and MSK Alumni
$200  Nurses, PAs, and other Healthcare Professionals
$100  Residents and Fellows

Registration includes continental breakfast, lunch, and refreshment breaks. Special meals are available upon request, including vegetarian, kosher, or gluten-free. Please let us know if we can assist you with any special dietary needs.

To register, please go to: www.mskcc.org/lymphoma2016

The registration fee is waived for all MSK staff. However, you must register for the course by visiting the Continuing Medical Education page on OneMSK

OFFICE OF CONTINUING MEDICAL EDUCATION
Memorial Sloan Kettering Cancer Center
633 Third Avenue, 12th floor, New York, New York 10017
cme@mskcc.org

COURSE DESIGN
This symposium includes hands-on review of cases which will be intermixed with short didactic lectures. One workstation per participant.

EVALUATION
A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

ACCREDITATION STATEMENT
MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a maximum of 17.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for 17.25 AMA PRA Category 1 Credits™.

OUTCOMES MEASUREMENT SURVEY
Six months after the end of the course an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

FACULTY DISCLOSURE
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCOMMODATIONS
If you are traveling to MSK from out of town, we recommend that you reserve hotel rooms as early as possible. To make the planning a little easier, MSK has negotiated rates at select hotels in Manhattan. For a list of these hotels, please go to: www.mskcc.org/accommodations.